Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States

RATIONALE AND OBJECTIVE: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval. This real-world database study examined outcomes for adult patients switching...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Al-Dakkak, Imad, Garlo, Katherine, Ong, Moh-Lim, Tomazos, Ioannis, Mahajerin, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319830/
https://www.ncbi.nlm.nih.gov/pubmed/37415624
http://dx.doi.org/10.1016/j.xkme.2023.100683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319830/
https://www.ncbi.nlm.nih.gov/pubmed/37415624
http://dx.doi.org/10.1016/j.xkme.2023.100683

Ejemplares similares